09 · Novel biology & target watch
Novel biology & target watch
Bookmarks need a Mind Club sign-in. How sign-in works
Today’s card is for KRAS, the target of both lead items. Also in the journals this week: ferroptosis and immune escape, a relaxin receptor structure, and CAR-T in multiple sclerosis.
| Paper | Finding, as stated | Why it matters |
|---|---|---|
| Nature, 11.18 · 10.1038/s41586-026-11333-6 (opens another website in a new tab) | Ferroptotic cancer cells make PGE2 through a calcium and p38 MAPK route that suppresses CD8 T cell priming; blocking PGE2 restored tumor control in models | A rationale to pair ferroptosis inducers with PGE2 or p38 blockade; preclinical |
| Science, 11.19 · 10.1126/science.aei0135 (opens another website in a new tab) | Cryo-EM structures show relaxin-2 and AstraZeneca’s small molecule AZD5462 switch on the RXFP1 receptor in different ways | Structural basis for relaxin-pathway drugs in heart failure and fibrosis |
| Cell, 11.19 · 10.1016/j.cell.2026.10.044 (opens another website in a new tab) | CD19 CAR-T in five people with multiple sclerosis remodeled B cells in spinal fluid and lowered humoral markers | Five patients; the authors call for controlled trials |
Journal records via PubMed, 11.20.2026 Peer
Target Evidence Card: KRAS (RAS)
Two pan-RAS drugs reported pancreatic cancer data this week, both from single-arm studies. Daraxonrasib, FDA approved on 08.26.2026 after previously treated patients lived longer in a randomized trial, had a confirmed response rate of 60.7% in 61 first-line patients when added to gemcitabine and nab-paclitaxel. From a different trial, Erasca’s ERAS-0015 reported 44% in 25 previously treated patients. The randomized first-line test, RASolute 303, has not read out.
TEC-0017 · KRAS · ENSG00000133703V2 · PULLED 11.20.2026
HUMAN GENETICSNone foundNo evidence identified for pancreatic ductal adenocarcinoma (MONDO_0005184): Open Targets genetic association score 0; the link there is somatic (somatic mutation score 0.61). Non-small cell lung carcinoma (MONDO_0005233): no genetic association score; somatic 0.84. Top elsewhere: RASopathy (MONDO_0021060) 0.95, Noonan syndrome 3 0.94, cardiofaciocutaneous syndrome 2 0.90; gastric cancer 0.90; not support for this indication. Direction not established. Open Targets 26.09, checked 11.20.2026.
MECHANISMRAS GTPaseChEMBL target CHEMBL2189121, 11.20: two curated mechanisms, sotorasib (covalent) and adagrasib, both KRAS G12C inhibitors. Daraxonrasib has no mechanism there; its FDA label (section 12.1) calls it a RAS GTPase family inhibitor that hits wild-type and mutant KRAS, NRAS and HRAS. Erasca calls ERAS-0015 a pan-RAS molecular glue (company claim).
HOW CROWDED91active interventional trials on ClinicalTrials.gov (recruiting, not yet recruiting, active not recruiting, enrolling by invitation), all diseases, searched 11.20.2026. V1’s terms (sotorasib, adagrasib, daraxonrasib, olomorasib, divarasib, zoldonrasib, elironrasib, glecirasib, fulzerasib, garsorasib, calderasib, “KRAS inhibitor”) return 105 (v1: 101); ERAS-0015, added today, adds 2. Of these, 11 multi-target trials (basket, umbrella and platform trials and a Roche extension study) are counted separately, and 5 records that test no KRAS drug are left out. Combination, comparator and background-therapy trials count. Pan-RAS drugs count as aimed at the target. Phase 3 count: 26, Phase 2/3 counted with Phase 3.
THE BAR3FDA-approved products, including biosimilars: three originators, no biosimilars. Sotorasib (Lumakras, NDA 214665, 05.28.2021) and adagrasib (Krazati, NDA 216340, 12.12.2022), both G12C-selective, and daraxonrasib (Rasonque, NDA 220910, 08.26.2026), pan-RAS, counted because KRAS is among its targets. All three marketed (prescription) on Drugs@FDA, 11.20.2026. Only Rasonque covers pancreatic cancer, after prior systemic therapy or when multiagent therapy is not an option; none is approved first-line for patients who can take multiagent chemotherapy.
HOW IT WORKS
Think of KRAS as a light switch for cell growth that cancer mutations jam in the on position. Older drugs fit only one jammed type. Daraxonrasib and ERAS-0015 try to block any switch that’s on, mutant or normal.
1 · THE GROWTH SWITCH
KRAS belongs to the RAS GTPase family. Bound to GTP it is active and passes grow signals on; breaking GTP down to GDP switches it off.
DEMONSTRATED
2 · STUCK ON
Many cancers carry somatic KRAS mutations, often at codon 12 (G12C, G12D, G12V), and drugs that block mutant KRAS shrink such tumors in people. Open Targets scores the somatic link at 0.61 for pancreatic and 0.84 for lung cancer.
DEMONSTRATED
3 · WHAT THE DRUG TRIES
Daraxonrasib pairs with cyclophilin A and clamps active RAS, mutant or normal KRAS, NRAS and HRAS, per its label.
SUGGESTIVE
Solid: seen in people (any design, including genetic association). Dashed: animals or cells. Dotted: hypothesis or company claim. Line style shows where a step was seen, not proof.
EVIDENCE LADDER
DEMONSTRATEDBlocking active RAS lengthened survival in previously treated metastatic pancreatic cancer in a randomized, open-label Phase 3 (RASolute 302: median 13.2 versus 6.6 months in the primary G12X population, 13.2 versus 6.7 overall, HR 0.40 in both), and the FDA approved daraxonrasib for that setting on 08.26.2026. SUGGESTIVESingle-arm, company-reported results from different trials: daraxonrasib plus gemcitabine and nab-paclitaxel, first line, confirmed response rate 60.7% (n=61) and median progression-free survival 12.8 months; ERAS-0015 at 32 mg, previously treated, confirmed response rate 44% (n=25; 95% CI about 24 to 65%, our calculation), 69% in G12D or G12V (n=13). SPECULATIVEThat adding a pan-RAS drug to first-line chemotherapy lengthens survival over chemotherapy alone, the question RASolute 303 asks, or that blocking all active RAS beats mutant-selective drugs head to head.
Who’s running. Revolution Medicines leads, with daraxonrasib approved and Phase 3 trials in first-line (RASolute 303, NCT07491445) and adjuvant (RASolute 304, NCT07252232) pancreatic cancer and in lung cancer (RASolve 301, NCT06881784), plus its G12D-selective zoldonrasib (RASolute 305, NCT07621718; with daraxonrasib, NCT07805954; RASolve 308, NCT07777822). Incyte tests a G12D drug in first-line pancreatic cancer (DAWN-303, NCT07522073). Erasca’s ERAS-0015 is in Phase 1 (AURORAS-1, NCT06983743), and Erasca says a first-line pancreatic Phase 3 should start in the first half of 2027. In G12C, Lilly, Roche, Merck, Amgen, Mirati (BMS) and Chia Tai Tianqing run Phase 3 trials. RASolute 302’s record (NCT06625320) reads active, not recruiting, past its 06.2026 primary completion date. Verified Erasca’s Phase 3 timing is a company plan. Claim
V1 · 10.16.2026First published as a library card, not printed V2 · 11.20.2026Edition 052. Recounted under rule A: headline 101 to 91, Phase 3 28 to 26; approved 3; first-line and ERAS-0015 data added
Open Targets Platform: KRAS (ENSG00000133703) associations, release 26.09, 11.20.2026 (opens another website in a new tab) Data. ChEMBL target CHEMBL2189121 (GTPase KRas) mechanisms, 11.20.2026 (opens another website in a new tab) Data. ClinicalTrials.gov search by drug name, 11.20.2026, interventional, active statuses; AURORAS-1 record NCT06983743 (opens another website in a new tab) Reg. RASolute 303 record NCT07491445 (opens another website in a new tab) Reg. openFDA Drugs@FDA and Rasonque label (sections 1 and 12.1), 11.20.2026 (opens another website in a new tab) Gov. OncLive, 10.23.2026 (RASolute 302 survival and subgroups) (opens another website in a new tab) Press. RASolute 302, NEJM (10.1056/NEJMoa2605555) (opens another website in a new tab) Peer. Revolution Medicines, first-line daraxonrasib plus chemotherapy at ENA 2026, 11.19.2026 (company claims) (opens another website in a new tab) Co. Erasca, updated ERAS-0015 Phase 1 data, 11.20.2026, via StockTitan (company claims) (opens another website in a new tab) Co.
BLUE TEAM · THE CASEPan-RAS inhibition may earn a first-line role in metastatic pancreatic cancer, not only after chemotherapy fails. The anchor is randomized: median survival 13.2 versus 6.7 months overall in previously treated patients. From different, single-arm studies, first-line daraxonrasib with chemotherapy had a 60.7% confirmed response rate (n=61), and a second pan-RAS drug, ERAS-0015, reports responses too. The thesis would strengthen if RASolute 303 shows longer survival than chemotherapy alone. Analysis
RED TEAM · THE CATCH
Every first-line and ERAS-0015 number here is single-arm and company-reported, so none can show benefit over chemotherapy, and a response rate is not survival. ERAS-0015’s response rate is a secondary endpoint of a Phase 1 trial whose primary endpoints are safety and dose-limiting toxicity, and one patient died of treatment-related pneumonitis. RASolute 302 was open-label in previously treated patients; against first-line chemotherapy, its hazard ratio of 0.40 may shrink. Analysis